arrow_back Trending Legislation
Share share

REMEDY Act: Ending Drug Patent Extensions

This act aims to speed up the market entry of cheaper generic drugs. It limits pharmaceutical companies' ability to repeatedly extend patent protection for the same drug, potentially lowering drug prices and increasing accessibility for citizens.
Key points
Pharmaceutical companies will only be able to select one patent for protection against generic competition, shortening the wait for cheaper alternatives.
The changes aim to prevent practices that artificially prolong drug monopolies, potentially leading to lower prices and more choices for patients.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
REMEDY Act
Print number: S 2620
Sponsor: Sen. Durbin, Richard J. [D-IL]
Process start date: 2025-07-31
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about REMEDY Act: Ending Drug Patent Extensions

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 2620.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-07-31.

What are the main provisions?

Key points include:

  • Pharmaceutical companies will only be able to select one patent for protection against generic competition, shortening the wait for cheaper alternatives.
  • The changes aim to prevent practices that artificially prolong drug monopolies, potentially leading to lower prices and more choices for patients.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Durbin, Richard J. [D-IL].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

Analysis and Potential Impact of S 2620

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Courts and Law Economy